- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
San Carlos Today
By the People, for the People
Wall Street Zen Downgrades Tenaya Therapeutics to 'Sell'
Analysts cite concerns over the biotech company's future performance
Mar. 14, 2026 at 6:04am
Got story updates? Submit your updates here. ›
Wall Street Zen, a research firm, has downgraded shares of Tenaya Therapeutics (NASDAQ:TNYA) from a 'hold' rating to a 'sell' rating in a new research report. The move comes as analysts at the firm express concerns over the biotech company's outlook and future performance.
Why it matters
Tenaya Therapeutics is a clinical-stage biotech company focused on developing gene therapy solutions for cardiovascular diseases. The downgrade from Wall Street Zen could signal broader skepticism about the company's ability to successfully bring its pipeline of treatments to market and generate revenue.
The details
In the research note, Wall Street Zen analysts cited a number of factors contributing to the downgrade, including the company's recent stock price performance and concerns over the viability of its product candidates. Tenaya Therapeutics' shares have traded between $0.36 and $2.35 over the past 52 weeks, indicating significant volatility.
- Wall Street Zen issued the downgrade on Saturday, March 14, 2026.
The players
Wall Street Zen
A research firm that provides analysis and ratings on publicly traded companies.
Tenaya Therapeutics
A clinical-stage biotechnology company focused on developing gene therapy solutions for cardiovascular diseases.
What’s next
Investors will be closely watching Tenaya Therapeutics' upcoming earnings report and any updates on the company's clinical trials and regulatory approvals for its gene therapy candidates.
The takeaway
The downgrade from Wall Street Zen highlights the challenges facing Tenaya Therapeutics as it seeks to develop and commercialize its innovative gene therapy treatments for cardiovascular diseases. The company's stock performance and the analysts' concerns underscore the competitive and uncertain nature of the biotech industry.
